{
    "symbol": "CERE",
    "quarter": 4,
    "year": 2022,
    "date": "2023-02-22 19:18:04",
    "content": " Looking forward, we expect our G&A expenses to remain relatively consistent for 2023 as compared to the fourth quarter of 2022 and we will focus our R&D spending on our top priorities, including advancing our ongoing comprehensive Phase II program for Emraclidine schizophrenia in the recently initiated Phase I trial of Emraclidine in healthy elderly volunteers to support the development in Alzheimer's disease psychosis, initiating our Phase II trial for Darigabat in panic disorder and continuing the advancement of our other lead programs."
}